A Phase 2 interventional study of Celecoxib in Non Muscle Invasive Bladder Cancer, sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-22.
Sponsored by Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari · Phase 2, Interventional, and Treatment
The treatment of non-muscle invasive bladder cancer (NMIBC) is problematic given the variable natural history of the disease. Although contemporary treatment options are limited, new targets and new approaches are under investigation for preventing bladder cancer recurrence and progression. Among those, COX-2 is a promising target since plays an important role in urothelial carcinogenesis and iCOX-2 selective inhibitors, like celecoxib, effectively inhibit tumor development and growth and enhances survival, in bladder cancer in vitro and in vivo models.
Therefore, the investigators conducted a pilot study of celecoxib to prevent recurrence in patients with intermediate risk NMIBC.
1,616 studies on the registry are indexed under Urinary Bladder Neoplasms; 421 are open to participants now.
This study's enrollment of 58 is close to the median of 60 across 1,163 interventional studies indexed under Urinary Bladder Neoplasms.
Browse Urinary Bladder Neoplasms studies →Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari is the lead sponsor of 44 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients undergoing treatment with oral celecoxib
Drug: Celecoxib
Time to first recurrence
Time frame: 5 years
Safety assessed by description of grade 1-4 adverse events
Time frame: 5 years
No study locations are listed for this record.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari